XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 23.01

-3.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (11425)	8/20/1999 1:40:00 PM
From: opalapril	Read Replies (2) of 17367

<<It is clear however that the result of the P II trauma trial was not as spectacular as the P II meningococcemia trial. But it had statistical significance on the endpoints being used in P III even if they selected after the P II trial was over.>> George or anyone: To what extent was there a dosage difference in te two P-2 trials? Is there any reason to think Neuprex dosages can or should be increased?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next